Citius Oncology (CTOR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

CTOR · Stock Price

USD 0.90+0.01 (+0.90%)

Market Cap: $79.7M

Historical price data

Overview

Citius Oncology is a biopharmaceutical company with a mission to develop and commercialize targeted oncology therapies by focusing on programs with potentially reduced development and clinical risks. Its defining achievement is the FDA approval of LYMPHIR™ (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma (CTCL) in August 2024, transitioning the company to a commercial entity. The core strategy involves leveraging existing clinical data, intellectual property, and regulatory exclusivity to expedite the path to market for treatments addressing high unmet medical need in oncology.

OncologyHematology

Technology Platform

A strategic development platform focused on de-risked asset development, leveraging existing clinical proof-of-concept, regulatory designations, and targeting well-defined oncology populations with high unmet need to expedite the path to market.

Opportunities

The primary opportunity is the successful commercial launch and market penetration of LYMPHIR™ in the underserved relapsed/refractory CTCL population, establishing a revenue base.

This commercial infrastructure could then be leveraged to in-license or acquire additional de-risked oncology assets, building a targeted oncology franchise.

Risk Factors

The company faces extreme concentration risk as its entire value depends on one newly launched product, coupled with unproven commercial execution capabilities.

Financial sustainability is a concern given the high costs of a launch, and the lack of a disclosed robust pipeline presents long-term growth risk.

Competitive Landscape

LYMPHIR™ competes in the relapsed/refractory CTCL market against other systemic therapies like mogamulizumab, HDAC inhibitors, and brentuximab vedotin. Its differentiation will rely on its unique mechanism, clinical profile, and commercial execution. As a company, it competes with numerous biotechs and large pharma in the targeted oncology space.

More companies in Oncology (General) →More companies in United States →